Loading
Obesity / Heart Failure With Preserved Ejection Fraction (HFPEF) / Cardiomyopathy · Phase 4 Trial
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed Phase 4 registry record describing a semaglutide trial in obesity-related HFpEF with primary endpoint of pulmonary capillary wedge pressure at 12 months. No results are posted in this registry entry, so no efficacy or safety conclusions can be drawn.
Phase 4, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity; age from 18 Years. Intervention: Semaglutide Treatment. Compared with: Placebo Treatment — Placebo Comparator. n = 81. 1 site: United States.
This is a completed Phase 4 registry record describing a semaglutide trial in obesity-related HFpEF with primary endpoint of pulmonary capillary wedge pressure at 12 months. No results are posted in this registry entry, so no efficacy or safety conclusions can be drawn.
Results are not yet posted in this registry record; no outcome data, effect sizes, or safety findings are available for review. Secondary endpoints, adverse events, and metabolic measures are not detailed in this record.
Clinicians should await publication of results from this completed trial to assess whether semaglutide improves hemodynamic or symptom burden in obese HFpEF patients. The primary endpoint (PCWP) is mechanistically relevant but this registry record alone provides no evidence of clinical benefit.
This is a completed Phase 4 registry record with no posted results; the study design and primary endpoint are stated but outcomes remain unreported.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should await publication of results from this completed trial to assess whether semaglutide improves hemodynamic or symptom burden in obese HFpEF patients. The primary endpoint (PCWP) is mechanistically relevant but this registry record alone provides no evidence of clinical benefit.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05371496). This is a study registration, not published results. Lead sponsor: Mayo Clinic. Recruitment status: COMPLETED. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 81 participants (ACTUAL). Conditions: Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity. Interventions: DRUG: Semaglutide; DRUG: Placebo; BEHAVIORAL: Counselling on healthy lifestyle intervention. Primary outcome measures: Pulmonary Capillary Wedge Pressure (PCWP) , Baseline, 12 months. Brief summary: The purpose of this research is to find out if an aggressive intervention to lose weight, will improve symptoms in patients with obesity-related cardiomyopathy, which is also known as the obese phenotype of heart failure with preserved ejection fraction (HFpEF).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.